Mechanisms of immune privilege in the posterior eye

International Reviews of Immunology

Volumn 32, Issue 1, 2013, Pages 42-56

  Stein Streilein, Joan ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Immune regulation; Immune suppression; Retina; Retinal pigmented epithelium (RPE)

Indexed keywords

ALPHA INTERMEDIN; CALCITONIN GENE RELATED PEPTIDE; CD200 ANTIGEN; CD200 RECEPTOR; CYCLIC AMP; FAS LIGAND; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE Y; PIGMENT EPITHELIUM DERIVED FACTOR; PROGRAMMED DEATH 1 LIGAND 1; RETINOIC ACID; THROMBOSPONDIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; BONE MARROW CELL; CELL ACTIVATION; CELL DEATH; CELL INVASION; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CELL SURVIVAL; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DOWN REGULATION; EFFECTOR CELL; GENE ACTIVATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE PRIVILEGE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NERVE CELL INHIBITION; ORGAN TRANSPLANTATION; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA NERVE CELL; REVIEW; SUBRETINAL NEOVASCULARIZATION; SUPPRESSOR CELL;

AGED; AGING; ANIMALS; DISEASE MODELS, ANIMAL; EYE DISEASES; HUMANS; IMMUNE TOLERANCE; POSTERIOR EYE SEGMENT; RETINAL PIGMENT EPITHELIUM;

EID: 84873295436     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.740535     Document Type: Review

References (130)

1. Stein-Streilein J. Immune regulation and the eye. Trends Immunol 2008;29(11):503-586. Epub 2008/11/08.
2. Streilein JW.Ocular immune privilege: therapeutic opportunities froman experiment of nature.Nat Rev Immunol 2003;3:878-889.
3. van Dooremaal JC. Die Entwicklung der in fremden Grund versetzen lebenden Gewebe. Albrecht Von Graefes Arch Ophthalmol 1873;19:358-373.
4. Medawar PB. A second study of the behavior and fate of skin homografts in rabbits. (A report to the WarWounds Committee of theMedical Research Council). J Anat 1945;79:157-188.
5. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. I. F1-lymphocyte-induced immune deviation. J Immunol 1977;118(3):809-814. (Pubitemid 8070859)
6. Wenkel HSJ. Analysis of immune deviation eleicited by antigens injected into the subretinal space. Invest Opthahalmol Vis Sci 1998;39(10):1823-1834.
7. Sonoda KH, Sakamoto T, Qiao H, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology 2005;116(3):390-399. (Pubitemid 41532130)
8. WenkelH, Streilein JW. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci 1998;39(10):1823-1834. (Pubitemid 28397264)
9. Sugita S, Keino H, Futagami Y, et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci 2006;47(12):5376-5384. (Pubitemid 46723788)
10. Sugita S, Futagami Y, Smith SB, et al. Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta. Exp Eye Res 2006;83(6):1459-1471. (Pubitemid 44648106)
11. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991;32:2201-2211.
12. Taylor AW.Neuropeptides, aqueous humor, and ocular immune privilege. In: Troger J, KieslbachG, Bechrakis N, editors. Neuropeptides in the eye. Kerala, India: Research Signpost; 2009. pp. 79-91.
13. Lin HH, Faunce DE, Stacey M, et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 2005;201(10):1615-1625. (Pubitemid 40721005)
14. McKnight AJ, Gordon S.TheEGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol 1998;63(3):271-280. (Pubitemid 28106839)
15. Chen L, Yang P, Kijlstra A. Distribution,markers, and functions of retinalmicroglia. Ocul Immunol Inflamm 2002;10(1):27-39.
16. Morris L, GrahamCF, Gordon S.Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. Development 1991;112(2):517-526.
17. Broderick C, Hoek RM, Forrester JV, et al. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002;161(5):1669-1677. Epub 2002/11/05. (Pubitemid 35265526)
18. Dick AD, Carter D, Robertson M, et al. Control of myeloid activity during retinal inflammation. J Leukoc Biol 2003;74(2):161-166. Epub 2003/07/30. (Pubitemid 38040411)
19. Chen L, Sham CW, Chan AM, et al. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci 2009;50(10):4941-4948. Epub 2009/05/08.
20. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242. Epub 2010/07/20.
21. Wenkel H, Streilein JW. Evidence that retinal pigment epithelium functions as an immuneprivileged tissue. Invest Ophthalmol Vis Sci 2000;41(11):3467-3473.
22. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy 2007;92:86-93. Epub 2007/02/01. (Pubitemid 47096898)
23. Ishida K, Panjwani N, Cao Z, Streilein JW. Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms. Ocul Immunol Inflamm 2003;11(2):91-105. (Pubitemid 37088581)
24. Sugita S, Usui Y,Horie S, et al. T-cell suppression by programmedcell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci 2009;50(6):2862-2870. Epub 2009/02/03.
25. Sugita S. Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp (Warsz) 2009;57(4):263-268. Epub 2009/07/02.
26. Usui Y, Okunuki Y,Hattori T, et al. Functional expression of B7H1 on retinal pigment epithelial cells. Exp Eye Res 2008;86(1):52-59. Epub 2007/11/06. (Pubitemid 350212878)
27. Sugita S, Horie S, Nakamura O, et al. Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol 2008;181(11):7525-7536.
28. Willermain F, Caspers-Velu L, Nowak B, et al. Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible implication in the immune privilege of the eye. Br J Ophthalmol 2002;86(12):1417-1421. Epub 2002/11/26. (Pubitemid 35408647)
29. Chen L, Pai V, Levinson R, et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm 2009;17(1):47-55. Epub 2009/03/19.
30. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. NatMed 1999;5(3):292-297. Epub 1999/03/23. (Pubitemid 29124364)
31. Wahlsten JL, Gitchell HL, Chan CC, et al. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. J Immunol 2000;165(10):5480-5486. Epub 2000/11/09.
32. Granstein RD, Staszewski R, Knisely TL, et al. Aqueous humor contains transforming growth factor-β and a small (<3500 daltons) inhibitor of thymocyte proliferation. J Immunol 1990;144(10):3021-3027. (Pubitemid 20149474)
33. Streilein JW, Cousins SW. Aqueous humor factors and their effect on the immune response in the anterior chamber. Curr Eye Res 1990;9(Suppl):175-182. (Pubitemid 20295620)
34. Apte RS, Sinha D,Mayhew E, et al. Role ofmacrophagemigration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998;160(12):5693-5696. (Pubitemid 28298023)
35. Ferguson TA, Griffith TS.Therole of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy 2007;92:140-154. (Pubitemid 47096903)
36. Ferguson TA, Griffith TS. A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 2006;213:228-238. Epub 2006/09/16. (Pubitemid 44401504)
37. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy 2007;92:71-85. (Pubitemid 47096897)
38. Streilein JW, Stein-Streilein J. Does innate immune privilege exist? J Leukoc Biol 2000;67(4): 479-487.
39. Stein-Streilein J, Taylor AW. An eye's view of T regulatory cells. J Leukoc Biol 2007;81(3):593-598. (Pubitemid 46393536)
40. Streilein JW, Okamoto S, Sano Y, Taylor AW. Neural control of ocular immune privilege. Ann N Y Acad Sci 2000;917:297-306.
41. Ng TF, Kitaichi N, Taylor AW. In vitro generated autoimmune regulatory T cells enhance intravitreous allogeneic retinal graft survival. Invest Ophthalmol Vis Sci 2007;48(11):5112-5117. Epub 2007/10/27. (Pubitemid 351260921)
42. Taylor A. A review of the influence of aqueous humor on immunity. Ocul Immunol Inflamm 2003;11(4):231-241. (Pubitemid 38021420)
43. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulatingmacrophage activation. Invest Ophthalmol Vis Sci 2006;47(9):3912-3918. (Pubitemid 46044306)
44. Streilein JW, Wilbanks GA, Taylor A, Cousins S. Eye-derived cytokines and the immunosuppressive intraocularmicroenvironment. Curr Eye Res 1992;11(Suppl):41-47.
45. Li MO,Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
46. KriegelMA, Li MO, Sanjabi S, et al. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006;8(2):138-144. (Pubitemid 44623982)
47. Kezuka T, Streilein JW. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber associated immune deviation. Invest Ophthalmol Vis Sci 2000;41: 1803-1811. (Pubitemid 30354352)
48. Kezuka T, Streilein JW(editors). Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells. Invest Ophthalmol Vis Sci 2000;41(6):1410-1421. (Pubitemid 30261864)
49. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 1992;11:1199-1206. (Pubitemid 23057729)
50. Taylor AW, Kitaichi N, Taylor AW. Melanocortin 5 receptor and ocular immunity. Cell Mol Biol 2006;52:141-147.
51. Taylor AW. Ocular immune privilege. Eye 2009;23:1885-1889. Epub 2009/01/13.
52. Taylor AW, Lee DJ. The alpha-melanocyte stimulating hormone induces conversion of effector T cells into treg cells. J Transplant 2011;2011:246856. Epub 2011/09/24.
53. Luttrull JK,Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabeticmacular edema: a review. Curr Diabetes Rev 2012;8(4):274-284. Epub 2012/05/17.
54. Lee DJ, Taylor AW. Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen. Invest Ophthalmol Vis Sci 2011;52(12):8862-8867. Epub 2011/10/13.
55. Szliter EA, Lighvani S, Barrett RP, Hazlett LD. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J Immunol 2007;178(2):1105-1114. Epub 2007/01/05. (Pubitemid 46098857)
56. DelgadoM, Pozo D, Ganea D.Thesignificance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56(2):249-290. (Pubitemid 38720831)
57. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999;162(3):1707-1716. Epub 1999/02/11. (Pubitemid 29307049)
58. Martinez C, Delgado M, Pozo D, et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol 1998;85(2):155-167. Epub 1998/06/18. (Pubitemid 28313500)
59. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999;162(8):4685-4696. Epub 1999/04/14. (Pubitemid 29314869)
60. Catalani E, Gangitano C, Bosco L, Casini G. Expression of the neurokinin 1 receptor in the mouse retina. Neuroscience 2004;128(3):519-530. Epub 2004/09/24. (Pubitemid 39277422)
61. Marriott I, Bost KL. Expression of authentic substance P receptors inmurine and human dendritic cells. J Neuroimmunol 2001;114(1-2):131-141. Epub 2001/03/10. (Pubitemid 32184734)
62. Holzer P,Holzer-Petsche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther 1997;73(3):219-263. Epub 1997/01/01.
63. Qiao H, Lucas K, Stein-Streilein J. Retinal laser burn disrupts immune privilege in the eye. Am J Pathol 2009;174(2):414-422. Epub 2009/01/17.
64. Masli S, Turpie B, Hecker KH, Streilein JW. Expression of thrombospondin in TGFbetatreated APCs and its relevance to their immune deviation-promoting properties. J Immunol 2002;168(5):2264-2273. Epub 2002/02/23. (Pubitemid 34171826)
65. Masli S, Turpie B, Streilein JW.Thrombospondin orchestrates the tolerance-promoting properties of TGF{beta}-treated antigen-presenting cells. Int Immunol 2006;18(5):689-699. (Pubitemid 43779059)
66. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74(2):179-185. (Pubitemid 38040414)
67. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155(2):441-452. (Pubitemid 29370394)
68. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000;12(5):634-640. Epub 2000/09/09.
69. Sheibani N, Sorenson CM, Cornelius LA, FrazierWA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000;267(1):257-261. (Pubitemid 30072539)
70. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity 2011;35(1):13-22. Epub 2011/07/23.
71. Doyle JW,Dowgiert RK, Buzney SM. Retinoic acid metabolism in cultured retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1995;36(3):708-717. Epub 1995/03/01.
72. Lee SA, Belyaeva OV, Popov IK, Kedishvili NY. Overproduction of bioactive retinoic acid in cells expressing disease-associated mutants of retinol dehydrogenase 12. J Biol Chem 2007;282(49):35621-35628. Epub 2007/10/11. (Pubitemid 350277123)
73. Zhou R, Horai R, Mattapallil MJ, Caspi RR. A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid. J Immunol 2011;187(8):4170-4177. Epub 2011/ 09/16.
74. Mucida D, Cheroutre H. TGF beta and retinoic acid intersect in immune-regulation. Cell AdhMigr 2007;1(3):142-144. Epub 2007/07/01.
75. Kawazoe Y, Sugita S, Keino H, et al. Retinoic acid fromretinal pigment epithelium induces T regulatory cells. Exp Eye Res 2012;94(1):32-40. Epub 2011/11/26.
76. Anderson DH,Mullins RF,HagemanGS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. AmJ Ophthalmol 2002;134(3):411-431.
77. Coleman HR, Chan CC, Ferris FL, 3rd, Chew EY. Age-related macular degeneration. Lancet 2008;372(9652):1835-1845. Epub 2008/11/26.
78. Sohn JH, Bora PS, Jha P, et al. Complement, innate immunity and ocular disease. Chem Immunol Allergy 2007;92:105-114. (Pubitemid 47096900)
79. Goslings WRO, Prodeus AP, Streilein JW, et al. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Visual Sci 1998;39:989-995. (Pubitemid 28196684)
80. Chang JH, McCluskey PJ, Wakefield D. Recent advances in Toll-like receptors (TLRs) and anterior uveitis. Clin Experiment Ophthalmol 2012. Epub 2012/03/21.
81. Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006;90(1):103-108. Epub 2005/12/20. (Pubitemid 43029907)
82. Jha P, Bora PS, Sohn JH, et al. Complement system and the eye. Adv ExpMed Biol 2006;586:53-62.
83. Sohn JH, Bora PS, Suk HJ, et al. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. NatMed 2003;9(2):206-212. (Pubitemid 36227723)
84. Copland DA,Calder CJ, Raveney BJ, et al.Monoclonal antibody-mediatedCD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007;171(2):580-588. Epub 2007/06/30. (Pubitemid 47344690)
85. Warfvinge K, Kamme C, Englund U, Wictorin K. Retinal integration of grafts of brain-derived precursor cell lines implanted subretinally into adult, normal rats. Exp Neurol 2001;169(1):1-12. Epub 2001/04/21. (Pubitemid 32424317)
86. Robertson MJ, Erwig LP, Liversidge J, et al. Retinal microenvironment controls resident and infiltratingmacrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002;43(7):2250-2257. (Pubitemid 34700655)
87. Minas K, Liversidge J. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol 2006;26(3):213-230. Epub 2006/08/25. (Pubitemid 44079772)
88. Chacko DM, Rogers JA, Turner JE, Ahmad I. Survival and differentiation of cultured retinal progenitors transplanted in the subretinal space of the rat. Biochem Biophys Res Commun 2000;268(3):842-846. Epub 2000/02/19. (Pubitemid 30150879)
89. Kiilgaard JF, Scherfig E, Prause JU, la Cour M. Transplantation of amniotic membrane to the subretinal space in pigs. Stem Cells Int 2012;2012:716968. Epub 2012/05/03.
90. YoungMJ, Ray J, Whiteley SJ, et al. Neuronal differentiation and morphological integration of hippocampal progenitor cells transplanted to the retina of immature and mature dystrophic rats.Mol Cell Neurosci 2000;16(3):197-205. Epub 2000/09/21.
91. Takahashi M, Palmer TD, Takahashi J, Gage FH. Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina. Mol Cell Neurosci 1998;12(6):340-348. Epub 1999/01/16. (Pubitemid 29048387)
92. Jiang LQ, Jorquera M, Streilein JW, Ishioka M. Unconventional rejection of neural retinal allografts implanted into the immunologically privileged site of the eye. Transplantation 1995;59(8):1201-1207. Epub 1995/04/27.
93. Jiang LQ, JorqueraM, Streilein JW. Immunologic consequences of intraocular implantation of retinal pigment epithelial allografts. Exp Eye Res 1994;58(6):719-728. Epub 1994/06/01. (Pubitemid 24252920)
94. Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH). Ann N Y Acad Sci 2000;917:239-247. Epub 2001/03/28.
95. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9(5):353-363. Epub 2009/04/15.
96. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005;121(5):671-674. Epub 2005/06/07. (Pubitemid 40797590)
97. Sugita S, Usui Y, Horie S, et al. Human corneal endothelial cells expressing programmed deathligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci 2009;50(1):263-272. Epub 2008/09/09.
98. Hori J,Wang M,MiyashitaM, et al. B7-H1-induced apoptosis as amechanism of immune privilege of corneal allografts. J Immunol 2006;177(9):5928-5935. (Pubitemid 44628806)
99. El Annan J,Goyal S, ZhangQ, et al. Programmeddeath-ligand 1 (PD-L1) regulates T cell chemotaxis in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci 2010;51(7):3418-3423. Epub 2009/12/19.
100. Griffith TS, Yu X, Herndon JM, et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996;5(1):7-16. Epub 1996/07/01. (Pubitemid 26254781)
101. Muller G, Muller A, Tuting T, et al. Interleukin-10-treated dendritic cells modulate immune responses of naive and sensitized T cells in vivo. J Invest Dermatol 2002;119:836-841. (Pubitemid 35340908)
102. Ferguson TA, Choi J, Green DR. Armed response: how dying cells influence T-cell functions. Immunol Rev 2011;241(1):77-88. Epub 2011/04/15.
103. Medawar PB. Immunity to homologous grafted skin. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948;29(1):58-69.
104. Kelly TL, Williams KA, Coster DJ. Corneal transplantation for keratoconus: a registry study. Arch Ophthalmol 2011;129(6):691-697. Epub 2011/02/16.
105. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34(12):3347-3354. Epub 1993/ 11/01. (Pubitemid 23346667)
106. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34:3347-3354. (Pubitemid 23346667)
107. Jiang LQ, Streilein JW. Immune privilege extended to allogeneic tumor cells in the vitreous cavity. Invest Ophthalmol Vis Sci 1991;32:224-228.
108. Jiang LQ, Streilein JW,McKinney C. Immune privilege in the eye: an evolutionary adaptation. Dev Comp Immunol 1994;18(5):421-431. Epub 1994/09/01. (Pubitemid 24379416)
109. Klassen H, Kiilgaard JF,Warfvinge K, et al. Photoreceptor differentiation following transplantation of allogeneic retinal progenitor cells to the dystrophic rhodopsin Pro347Leu transgenic pig. Stem Cells Int 2012;2012:939801. Epub 2012/05/09.
110. Klassen H, Ziaeian B, Kirov II, et al. Isolation of retinal progenitor cells from post-mortem human tissue and comparisonwith autologous brain progenitors. JNeurosci Res 2004;77(3):334-343. Epub 2004/07/13. (Pubitemid 38970977)
111. Klassen HJ, Ng TF, Kurimoto Y, et al.Multipotent retinal progenitors express developmentalmarkers, differentiate into retinal neurons, and preserve light-mediated behavior. InvestOphthalmol Vis Sci 2004;45(11):4167-4173. Epub 2004/10/27. (Pubitemid 39411176)
112. Ohta K, Wiggert B, Taylor AW, Streilein JW. Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 1999;40(9):2010-2018. (Pubitemid 29365164)
113. Mo JS, Streilein JW. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001;31(12):3806-3815. (Pubitemid 34030995)
114. Lucas K, KaramichosD,Mathew R, et al. Retinal laser burn-induced neuropathy leads to substance p-dependent loss of ocular immune privilege. JImmunol 2012;189(3):1237-1242. Epub 2012/06/30.
115. Ferguson TA, Fletcher S, Herndon J, Griffith TS. Neuropeptides modulate immune deviation induced via the anterior chamber of the eye. J Immunol 1995;155:1746-1756.
116. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010;29(6):500-519. Epub 2010/05/22.
117. Grossniklaus HE, Green WR. Choroidal neovascularization. AmJ Ophthalmol 2004;137(3):496-503. Epub 2004/03/12. (Pubitemid 38328642)
118. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-relatedmacular degeneration. Prog Retin Eye Res 2001;20(6):705-732. Epub 2001/10/06. (Pubitemid 32918285)
119. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and agerelated macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J: official publication of the Federation of American Societies for Experimental Biology 2000;14(7):835-846. Epub 2000/04/27. (Pubitemid 30241660)
120. Penfold PL,Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects ofmacular degeneration. Prog Retin Eye Res 2001;20(3):385-414. Epub 2001/04/05. (Pubitemid 32245687)
121. UetaM,Hamuro J,Kiyono H,Kinoshita S.Triggering of TLR3 by poly I:Cinhumancorneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res Commun 2005;331(1):285-294. (Pubitemid 40545174)
122. Ueta M, Nochi T, Jang MH, et al. Intracellularly expressed TLR2s and TLR4s contribution to an immunosilent environment at the ocular mucosal epithelium. J Immunol 2004;173(5):3337-3347. Epub 2004/08/24. (Pubitemid 39142043)
123. Zhang J, Xu K, Ambati B, Yu FS. Toll-like receptor 5-mediated corneal epithelial inflammatory responses to Pseudomonas aeruginosa flagellin. Invest Ophthalmol Vis Sci 2003;44(10):4247-4254. Epub 2003/09/26. (Pubitemid 37186258)
124. Song PI, Abraham TA, Park Y, et al. The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci 2001;42(12):2867-2877. Epub 2001/11/01. (Pubitemid 33035285)
125. Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to Staphylococcus aureus infection: role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci 2004;45(10):3513-3522. Epub 2004/09/29. (Pubitemid 39298569)
126. Kumagai N, Fukuda K, Fujitsu Y, et al. Lipopolysaccharide-induced expression of intercellular adhesion molecule-1 and chemokines in cultured human corneal fibroblasts. Invest Ophthalmol Vis Sci 2005;46(1):114-1120. Epub 2004/12/30.
127. Chang JH, McCluskey P, Wakefield D. Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen-presenting cells in the human uvea. Invest Ophthalmol Vis Sci 2004;45(6):1871-1878. (Pubitemid 38868984)
128. Brito BE, Zamora DO, Bonnah RA, et al. Toll-like receptor 4 and CD14 expression in human ciliary body and TLR-4 in human iris endothelial cells. Exp Eye Res 2004;79(2):203-208. Epub 2004/08/25. (Pubitemid 39119409)
129. Kumar MV, Nagineni CN, Chin MS, et al. Innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol 2004;153(1-2):7-15. Epub 2004/07/22. (Pubitemid 38950922)
130. Kindzelskii AL, Elner VM, Elner SG, et al. Toll-like receptor 4 (TLR4) of retinal pigment epithelial cells participates in transmembrane signaling in response to photoreceptor outer segments. J Gen Physiol 2004;124(2):139-149. Epub 2004/07/28. (Pubitemid 39038188)